Myeloma Today: Fall 2022
The Fall edition of Myeloma Today has articles about TECVAYLI™(teclistamab-cqyv), the first-in-class bispecific BCMA-directed CD3 T-cell engager that has been granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory myeloma, as well as a summary of treatment options for patients with myeloma after 1–3 prior lines of therapy and treatment with CAR T after 4 or more prior lines of therapy.